Curis Inc. (CRIS: Quote) announced the presentation of data in a poster session at the American Association for Cancer Research or AACR Annual Meeting 2012 in Chicago, Illinois.
The poster presentation, titled "Antitumor Activity of CUDC-907, a Dual PI3K and HDAC Inhibitor in Hematological Cancer Models", was presented by Rudi Bao, M.D., Ph.D., Curis' Senior Director of Oncology.
The company noted that the poster presentation focused on CUDC-907's biologic activity in cell culture and animal models of various hematological cancers, with a particular focus on multiple myeloma and B-cell lymphoma. In in vitro and in vivo testing, CUDC-907 outperformed a first-in-class HDAC inhibitor as well as an investigational pan-PI3K (Class I) inhibitor given as a single agent or in a combination of both agents.
CUDC-907 also demonstrated enhanced antitumor activity in animal models of B-cell lymphoma and multiple myeloma when co-administered with standard of care agents used in the treatment of patients with these malignancies.
Furthermore, this poster showed that many commonly used in vivo models of B-cell lymphoma and multiple myeloma expressed various PI3K Class I isoforms, suggesting that a pan-PI3K inhibitor such as CUDC-907 may be of greater benefit in many cases than a PI3K inhibitor that is focused narrowly on one PI3K isoform.
The company stated that CUDC-907 showed greater biologic activity than a delta-specific investigational inhibitor in a number of hematological cancer cells in vitro, and showed greater growth-inhibitory activity in an animal model of non-Hodgkin's Lymphoma.
| || |
| To receive FREE breaking news email alerts for Curis Inc and others in your portfolio|
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org